Effects of levothyroxine suppressive therapy on bone mineral density in premenopausal women

Journal of Clinical Pharmacy and Therapeutics

Volumn 29, Issue 1, 2004, Pages 1-5

  Larijani, B ^a,d   Gharibdoost, F ^a   Pajouhi, M ^a   Sadjadi, A ^b   Aghakhani, S ^b   Eshraghian, R ^a   Akrami, S M ^a   Maalouf, G ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c SAINT GEORGE HOSPITAL UNIVERSITY MEDICAL CENTER   (Lebanon)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Levothyroxine; Premenopausal women; Suppressive therapy

Indexed keywords

CALCIUM; LEVOTHYROXINE; LIOTHYRONINE; PARATHYROID HORMONE; PHOSPHATE; SODIUM; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; LABORATORY TEST; LIOTHYRONINE BLOOD LEVEL; LUMBAR SPINAL CORD; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREMENOPAUSE; RISK ASSESSMENT; SODIUM URINE LEVEL; THYROID NODULE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADULT; BONE DENSITY; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; PREMENOPAUSE; THYROID NODULE; THYROXINE;

EID: 1342267655     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0269-4727.2003.00508.x     Document Type: Article

References (32)

1. Delmas P, Adamis S, Christiansen C et al. (1993) Osteoporosis: today and beyond. Osteoporosis in Practice, 1, 3-5.
2. Hahn BH (1993) Osteoporotic bone disease. In: McCarty DJ, ed. Arthritis and allied conditions. Philadelphia, PA: Lea & Febriyer, 1927-1935.
3. Dargent P, Breart G (1993) Epidemiology and risk factors of osteoporosis. Current Opinion in Rheumatology (Review), 5, 339-345.
4. Seeman E (1993) Peak bone mass: a growing problem. In: Christiansen C, ed. Proceedings of 4th International Symposium on Osteoporosis. Aalborg, Denmark, 489-493.
5. Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N (1977) Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol (Copenhagen), 85, 515-525.
6. Ross D (1991) Monitoring L-thyroxine therapy: lessons from the effects of L-thyroxine on bone density. American Journal of Medicine, 91, 1-4.
7. Muller CG, Bayley TA, Harrison JE, Tsang R (1995) Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance. Thyroid, 5, 81-87.
8. Sheppard MC, Holder R, Franklyn JA (2002) Levothyroxine treatment and occurrence of fracture of the hip. Archives of Internal Medicine, 162, 338-343.
9. Ross DS, Neer RM, Ridgway EC, Daniels GH (1987) Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. American Journal of Medicine, 82, 1167-1170.
10. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT (1988) Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA, 259, 3137-3141.
11. Franklyn JA, Betteridge J, Daykin J, Holder R, Oates GD, Parle JV, Lilley J, Heath DA, Sheppard MC (1992) Long-term thyroxine treatment and bone mineral density. Lancet, 340, 9-13.
12. Hanna FW, Pettit RJ, Ammari F, Evans WD, Sandeman D, Lazarus JH. (1998) Effect of replacement doses of thyroxine on bone mineral density. Clinical Endocrinology (Oxford), 48, 229-234.
13. Nezam-Mafi S (1965) Various aspects of endemic goiter in Iran. Rev Med Moyen Orient, 22, 199-203.
14. Emami A, Shahbazi H, Sabzevari M et al. (1969) Goiter in Iran. American Journal of Clinical Nutrition, 22, 1584-1588.
15. Keyvani F, Yassai M, Kimiagar M (1988) Vitamin A status and endemic goiter. International Journal for Vitamin and Nutrition Research, 58, 155-160.
16. Azizi F, Navai L, Fattahi F (2002) Goiter prevalence, urinary iodine excretion, thyroid function and anti-thyroid function and anti-thyroid antibodies after 12 years of salt iodization in Shahriar, Iran. International Journal for Vitamin and Nutrition Research, 72, 291-295.
17. Rezvanian H, Aminorroaya A, Majlesi M, Amini A, Hekmatnia A, Kachoie A, Amini M, Emani J (2002) Thyroid size and iodine intake in iodine-repleted pregnant women in Isfahan, Iran. Endocrine-Practice, 8, 23-28.
18. Larijani B, Pajouhi M, Ghanaati H et al. (2002) Treatment of hyperfunctioning thyroid nodules by percutaneous ethanol injection. BMC Endocrine Disorder, 2, 3.
19. Mazzaferri EL (1993) Management of a solitary thyroid nodule. New England Journal of Medicine, 328, 553-559.
20. Cooper DS (1995) Clinical review 66: thyroxine suppression therapy for benign nodular disease. Journal of Clinical Endocrinology and Metabolism, 80, 331-334.
21. Larijani B, Pajouhi M, Bastanhagh MH, Sajadi A, Sedighi N, Eshraghian R (1999) Endocrine-practice. Evaluation of suppressive therapy for cold nodules with levothyroxine: double-blind placebo-controlled clinical trial. 5, 251-256.
22. Smith DA, Fraser SA, Wilson GM (1973) Hyperthyroidism and calcium metabolism. Clinical Endocrinology and Metabolism, 2, 333-354.
23. Diamond T, Nery L, Hales I (1991) A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 72, 1184-1188.
24. Kung AW, Lorentz T, Tam SC (1993) Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women. Clinical Endocrinology (Oxford), 39, 535-540.
25. Ribot C, Tremollieres F, Pouilles JM, Louvet JP (1990) Bone mineral density and thyroid hormone therapy. Clinical Endocrinology (Oxford), 33, 143-153.
26. Greenspan SL, Greenspan FS, Resnick NM, Block JE, Friedlander AL, Genant HK (1991) Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. American Journal of Medicine, 91, 5-14.
27. Lopez Alvarez MB, Hawkins F, Rigopoulou D, Martinez G, Jodar E, Estenoz J, Ortuno B, Arnaiz F (1999) The risk factors and bone mineral density in women on long-term levothyroxine treatment. Medicina Clinica, 112(3), 85-9.
28. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A (1994) Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. Journal of Clinical Endocrinology and Metabism, 78, 818-23.
29. Hawkins F, Rigopoulou D, Papapietro K, Lopez MB (1994) Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis. Calcified Tissue International, 54, 16-9.
30. Franklyn J, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M (1994) Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis. Clinical Endocrinology (Oxford), 41, 425-432.
31. Faber J, Galloe AM (1994) Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. European Journal of Endocrinology, 130, 350-356.
32. Toh H (1985) Effect of Hyperthyroidism and Its Treatment on Bone Mineral Content. Archives Internal Medicine, 145, 883-888.